BioNTech is turning out the lights at the Singapore plant and planned regional headquarters it purchased from Novartis at the height of the COVID-19 outbreak, reflecting a sharp reversal in the mRNA specialist’s trajectory since the pandemic’s end.
BioNTech announced the purchase of the Singapore facility from Novartis in November 2022, the same year the company logged sales of 17.3 billion euros thanks to its massively successful Pfizer-partnered COVID shot Comirnaty.
More recently, the company reported sales of 2.9 billion euros ($3.3 billion) for all of 2025. That reversal in commercial COVID fortunes isn’t unique to BioNTech—its partner Pfizer and rival Moderna have also suffered the sting of dwindling vaccine sales in recent years.
h/t A Deplorable Neanderthal